

Name | Size/Type | Description | Date |
---|---|---|---|
3-day TIP consent | 113KB PDF | 3-day TIP consent | 06 Jan 2021 |
Abemaciclib consent | 111KB PDF | Abemaciclib consent | 21 Apr 2020 |
Abraxane (nab-paclitaxel) & Gemcitabine consent | 113KB PDF | Abraxane (nab-paclitaxel) & Gemcitabine consent | 21 Apr 2020 |
Abraxane (Nab-paclitaxel) consent | 112KB PDF | Abraxane consent | 05 Jun 2020 |
Accelerated EC - Accelerated Paclitaxel consent | 114KB PDF | Accelerated EC - accelerated paclitaxel consent | 05 Jun 2020 |
Accelerated EC - Docetaxel consent | 114KB PDF | Accelerated EC - Docetaxel consent | 21 Apr 2020 |
Accelerated EC - Paclitaxel & Carboplatin consent | 115KB PDF | Accelerated EC - Paclitaxel & Carboplatin | 11 Aug 2020 |
Accelerated MVAC consent | 112KB PDF | 21 Apr 2020 | |
Afatinib consent | 109KB PDF | Afatinib consent | 21 Apr 2020 |
Alectinib consent | 98KB PDF | Alectinib consent | 30 Jan 2025 |
Alpelisib + Fulvestrant consent | 113KB PDF | 13 Feb 2023 | |
Atezolizumab + Abraxane consent | 116KB PDF | Atezolizumab + Abraxane consent | 02 Jun 2020 |
Atezolizumab + Bevacizumab consent | 132KB PDF | Atezolizumab + Bevacizumab consent | 20 Sep 2024 |
Atezolizumab s/c consent | 114KB PDF | Atezolizumab s/c consent | 18 Jan 2024 |
Atezolizumab, Bevacizumab, Paclitaxel & Carboplatin consent | 143KB PDF | Atezolizumab, Bevacizumab, Paclitaxel & Carboplatin consent | 18 Jan 2024 |
Atezolizumab, Carboplatin & Etoposide consent | 140KB PDF | Atezolizumab, Carboplatin & Etoposide consent | 18 Jan 2024 |
Avelumab and Axitinib consent | 141KB PDF | Avelumab and Axitinib consent | 17 Aug 2020 |
Avelumab consent | 112KB PDF | Avelumab consent | 21 Apr 2020 |
Axitinib consent | 111KB PDF | Axitinib consent | 21 Apr 2020 |
BEP consent | 115KB PDF | BEP consent | 28 Apr 2023 |
Bevacizumab + Trifluridine-Tipiracil (Lonsurf) consent | 119KB PDF | Bevacizumab + Trifluridine-Tipiracil (Lonsurf) consent | 26 Nov 2024 |
Bevacizumab consent | 112KB PDF | Bevacizumab consent | 21 Apr 2020 |
Bevacizumab, Paclitaxel & Carboplatin consent | 115KB PDF | Bevacizumab, Paclitaxel & Carboplatin consent | 21 Apr 2020 |
Brigatinib consent | 111KB PDF | Brigatinib consent | 21 Apr 2020 |
Cabazitaxel consent | 113KB PDF | Cabazitaxel consent | 21 Apr 2020 |
Cabozantinib consent | 113KB PDF | Cabozantinib consent | 22 Dec 2020 |
Caelyx (Liposomal Doxorubicin) consent | 113KB PDF | Caelyx (Liposomal Doxorubicin) consent | 21 Apr 2020 |
Caelyx & Carboplatin consent | 113KB PDF | Caelyx & Carboplatin consent | 21 Apr 2020 |
CAP consent | 113KB PDF | CAP consent | 21 Apr 2020 |
Capecitabine + MMC consent | 116KB PDF | Capecitabine + MMC consent | 01 Dec 2020 |
All consent forms on this website are for the use of St Luke’s Cancer Alliance staff in respect of St Luke’s Cancer Alliance patients only.
For those who do not work within St Luke’s Cancer Alliance:
Use of this site and any information on it is at your own risk. We do not accept responsibility for the use of any information that may be set out on the website. You assume full responsibility for the use of the information. You may wish to take your own legal advice before using any of the consent forms.
Please note that the consent forms below are not tumour-specific; one consent form may be used to consent patients for more than one St Luke’s Alliance chemotherapy protocol which uses the same combination of chemotherapy.
These consent forms should act as an aide-memoire to health professionals and patients, by providing a check-list of the kind of information which patients should be offered, and by enabling the patient to have a written record of the main points discussed.
The relevant Macmillan leaflet(s) should also be provided to each patient before consent. In no way should written information given to the patient be regarded as a substitute for face-to-face discussions with the patient.
These consent forms are for solid tumour chemotherapy only, and are NOT to be used for chemo-radiotherapy regimens.